By Michele Maatouk
Date: Tuesday 07 Apr 2026
(Sharecast News) - California-based Gilead Sciences said on Tuesday that it has agreed to buy German clinical stage biotechnology group Tubulis for up to $5bn.
| Currency | US Dollars |
| Share Price | $ 147.50 |
| Change Today | $ 0.00 |
| % Change | 0.00 % |
| 52 Week High | $155.80 |
| 52 Week Low | $110.56 |
| Volume | 781 |
| Shares Issued | 1,241.00m |
| Market Cap | $183,048m |
| Beta | 0.01 |
| RiskGrade | 120 |
You are here: research